This study identified nonpregnant adults with at least one outpatient encounter and serum creatinine assessment, focusing on ...

FDA approval of MIPLYFFATM and product launch cap third quarter filled with multiple commercial and clinical development milestones Zevra ...

Results: A ≥ 101% increment ... adjusted odds ratio of 2.66 (95% CI: 1.00–7.21). Patients in the ≥ 101% increment group had a higher mean serum creatinine level with respect to their ...

Fitness coach Lizzy High has shared the simple lifestyle changes she made to her routine in a bid to lose weight and tone up, ...

Announced Exclusive Licensing Agreement with Viatris for Sotagliflozin in all Markets Outside of the U.S. and Europe Completed ZYNQUISTA™ FDA Advisory Committee Meeting; PDUFA Goal Date December 20, ...

Detailed price information for Satellos Bioscience Inc (MSCL-T) from The Globe and Mail including charting and trades.

Advancing investigation of [212Pb]VMT01 as a monotherapy and in combination with the anti-PD-1 antibody, nivolumab, in patients with previously ...

Sunvozertinib has shown promising results in patients with non–small cell lung cancer with an EGFR exon 20 insertion mutation ...

Egypt: A recent randomized controlled trial has demonstrated that sitagliptin, a DPP-4 inhibitor, significantly improves ...

How to Keep Your Kidneys Healthy Despite Diabetes? Here Are The Top 5 Proven Strategies To Beat The Side Effects of High Blood Sugar Levels.

Updating US dialysis clinics to support hemodiafiltration technology would be necessary to enable its widespread adoption.

Announced Exclusive Licensing Agreement with Viatris for Sotagliflozin in all Markets Outside of the U.S. and Europe Completed ZYNQUISTA FDA Advisory Committee Meeting; PDUFA Goal Date December 20, 20 ...